Cited 7 times in
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.date.accessioned | 2024-03-22T05:54:59Z | - |
dc.date.available | 2024-03-22T05:54:59Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 1262-3636 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198285 | - |
dc.description.abstract | Aims: This study evaluated the efficacy and safety of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor, versus dapagliflozin in Korean patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and gemigliptin. Methods: In this multicenter, double-blind, randomized study, patients with inadequate response to metformin (≥ 1000 mg/day) plus gemigliptin (50 mg/day) were randomized to receive enavogliflozin 0.3 mg/day (n = 134) or dapagliflozin 10 mg/day (n = 136) in addition to the metformin plus gemigliptin therapy. The primary endpoint was change in HbA1c from baseline to week 24. Results: Both treatments significantly reduced HbA1c at week 24 (–0.92% in enavogliflozin group, –0.86% in dapagliflozin group). The enavogliflozin and dapagliflozin groups did not differ in terms of changes in HbA1c (between-group difference: –0.06%, 95% confidence interval [CI]: –0.19, 0.06) and fasting plasma glucose (between-group difference: –3.49 mg/dl [–8.08;1.10]). An increase in urine glucose-creatinine ratio was significantly greater in the enavogliflozin group than in the dapagliflozin group (60.2 g/g versus 43.5 g/g, P < 0.0001). The incidence of treatment-emergent adverse events was similar between the groups (21.64% versus 23.53%). Conclusions: Enavogliflozin, added to metformin plus gemigliptin, was well tolerated and as effective as dapagliflozin in the treatment of patients with T2DM. © 2023 The Author(s) | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, French | - |
dc.publisher | Masson | - |
dc.relation.isPartOf | DIABETES & METABOLISM | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Benzhydryl Compounds / adverse effects | - |
dc.subject.MESH | Blood Glucose | - |
dc.subject.MESH | Diabetes Mellitus, Type 2* / epidemiology | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Glycated Hemoglobin | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents / adverse effects | - |
dc.subject.MESH | Metformin* / adverse effects | - |
dc.subject.MESH | Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kyung-Soo Kim | - |
dc.contributor.googleauthor | Kyung Ah Han | - |
dc.contributor.googleauthor | Tae Nyun Kim | - |
dc.contributor.googleauthor | Cheol-Young Park | - |
dc.contributor.googleauthor | Jung Hwan Park | - |
dc.contributor.googleauthor | Sang Yong Kim | - |
dc.contributor.googleauthor | Yong Hyun Kim | - |
dc.contributor.googleauthor | Kee Ho Song | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.contributor.googleauthor | Chul Sik Kim | - |
dc.contributor.googleauthor | Gwanpyo Koh | - |
dc.contributor.googleauthor | Jun Goo Kang | - |
dc.contributor.googleauthor | Mi Kyung Kim | - |
dc.contributor.googleauthor | Ji Min Han | - |
dc.contributor.googleauthor | Nan Hee Kim | - |
dc.contributor.googleauthor | Ji Oh Mok | - |
dc.contributor.googleauthor | Jae Hyuk Lee | - |
dc.contributor.googleauthor | Soo Lim | - |
dc.contributor.googleauthor | Sang Soo Kim | - |
dc.contributor.googleauthor | Tae Ho Kim | - |
dc.contributor.googleauthor | Kyu Chang Won | - |
dc.contributor.googleauthor | Ki Young Lee | - |
dc.contributor.googleauthor | Jae Hyoung Cho | - |
dc.contributor.googleauthor | Ju Young Han | - |
dc.contributor.googleauthor | So Hun Kim | - |
dc.contributor.googleauthor | Jae Jin Nah | - |
dc.contributor.googleauthor | Hwa Rang Song | - |
dc.contributor.googleauthor | Si Eun Lee | - |
dc.contributor.googleauthor | Sungrae Kim | - |
dc.contributor.googleauthor | ENHANCE-D Investigators | - |
dc.identifier.doi | 10.1016/j.diabet.2023.101440 | - |
dc.contributor.localId | A00068 | - |
dc.relation.journalcode | J00719 | - |
dc.identifier.eissn | 1878-1780 | - |
dc.identifier.pmid | 36906135 | - |
dc.subject.keyword | Enavogliflozin | - |
dc.subject.keyword | HbA1c | - |
dc.subject.keyword | Phase III study | - |
dc.subject.keyword | Randomized controlled study | - |
dc.subject.keyword | Sodium-glucose cotransporter 2 inhibitor | - |
dc.subject.keyword | Type 2 diabetes mellitus | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | 강은석 | - |
dc.citation.volume | 49 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 101440 | - |
dc.identifier.bibliographicCitation | DIABETES & METABOLISM, Vol.49(4) : 101440, 2023-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.